Resistance to targeted therapies: A role for microRNAs?

Trends in Molecular Medicine

Volumn 19, Issue 10, 2013, Pages 633-642

  Migliore, Cristina ^a   Giordano, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Mechanisms of resistance; MiRNAs; Molecular therapies; Sensitivity to therapy

Indexed keywords

AFATINIB; AZD 8931; CETUXIMAB; DACOMITINIB; ERLOTINIB; FULVESTRANT; GEFITINIB; IMATINIB; LAPATINIB; MICRORNA; PANITUMUMAB; RALOXIFENE; SORAFENIB; TAMOXIFEN; TRASTUZUMAB;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR CELL;

MECHANISMS OF RESISTANCE; MIRNAS; MOLECULAR THERAPIES; SENSITIVITY TO THERAPY;

DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84884817403     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.08.002     Document Type: Review

References (83)

1. Gschwind A., et al. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
2. Calin G.A., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
3. Johnson S.M., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
4. Kumar M.S., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3903-3908.
5. He L., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
6. Meng F., et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
7. Asangani I.A., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
8. O'Donnell K.A., et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
9. Saito Y., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
10. Lujambio A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
11. Calin G.A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353:1793-1801.
12. Abelson J.F., et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005, 310:317-320.
13. Zhang L., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9136-9141.
14. Zhang L., et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7004-7009.
15. Jemal A., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
16. Weiss G.J., et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19:1053-1059.
17. Zhong M., et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem. Biol. Interact. 2010, 184:431-438.
18. Wang Y.S., et al. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 2012, 13:255-260.
19. Bryant J.L., et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br. J. Cancer 2012, 106:148-156.
20. Garofalo M., et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 2012, 18:74-82.
21. Grandis J.R., Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993, 53:3579-3584.
22. Mehra R., et al. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin. Adv. Hematol. Oncol. 2008, 6:742-750.
23. Hatakeyama H., et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE 2010, 5:e12702.
24. Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
25. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
26. Baker J.B., et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br. J. Cancer 2011, 104:488-495.
27. Allegra C.J., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
28. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28:1254-1261.
29. Mekenkamp L.J., et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012, 12:292.
30. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J. Clin. Invest. 2011, 121:3797-3803.
31. Ward A., et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013, 32:1173-1182.
32. Hu G., et al. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin. Cancer Res. 2009, 15:5615-5620.
33. Cittelly D.M., et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 2010, 9:317.
34. Bergamaschi A., Katzenellenbogen B.S. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012, 31:39-47.
35. Vogel V.G., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
36. Zhao J.J., et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.
37. Nam S., et al. An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics 2012, 13:732.
38. Mei M., et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol. Cancer Res. Treat. 2010, 9:77-86.
39. Wang Z.X., et al. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch. Med. Res. 2011, 42:281-290.
40. Gong C., et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 2011, 286:19127-19137.
41. Niu J., et al. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J. Biol. Chem. 2012, 287:21783-21795.
42. Messing E.M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999, 341:1781-1788.
43. Waltering K.K., et al. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell. Endocrinol. 2012, 360:38-43.
44. Lin P.C., et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013, 73:1232-1244.
45. Nadiminty N., et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J. Biol. Chem. 2012, 287:1527-1537.
46. Sikand K., et al. miR 488 inhibits androgen receptor expression in prostate carcinoma cells. Int. J. Cancer 2011, 129:810-819.
47. Ribas J., et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69:7165-7169.
48. Sun T., et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 2012, 72:1093-1103.
49. Sun T., et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2013, 10.1038/onc.2013.230.
50. Cortes S.M., et al. The role of the NFκB signalling pathway in cancer. Clin. Transl. Oncol. 2008, 10:143-147.
51. Shaulian E. AP-1 - the Jun proteins: oncogenes or tumor suppressors in disguise?. Cell. Signal. 2010, 22:894-899.
52. Ma S., et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 2011, 71:583-592.
53. Boll K., et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013, 32:277-285.
54. Druker B.J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
55. Oestreicher P. Drugs offer new hope for patients with CML who are resistant to imatinib. ONS Connect 2007, 22:20-21.
56. Lopotovà T., et al. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?. Leuk. Res. 2011, 35:974-977.
57. Scholl V., et al. miRNA-451: a putative predictor marker of imatinib therapy response in chronic myeloid leukemia. Leuk. Res. 2012, 36:119-121.
58. Liu L., et al. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem. Biophys. Res. Commun. 2012, 425:368-373.
59. San José-Enériz E., et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 2009, 8:69.
60. Llovet J.M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
61. Chang J., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004, 1:106-113.
62. Jopling C.L., et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005, 309:1577-1581.
63. Tsai W.C., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 2012, 122:2884-2897.
64. Bai S., et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009, 284:32015-32027.
65. Shimizu S., et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 2010, 52:698-704.
66. Xia H., et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013, 58:629-641.
67. Lawrie C.H., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
68. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
69. Shen J., et al. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013, 329:125-136.
70. Jung E.J., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118:2603-2614.
71. Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
72. Hao M., et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk. Lymphoma 2011, 52:1787-1794.
73. Lwin T., et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010, 116:5228-5236.
74. Driscoll J.J., et al. Microenvironment-induced changes in miRNA levels promote brain metastasis, drug resistance and KRAS expression. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR), April 6-10, 2013, Washington, DC 2013, Abstract nr LB-277.
75. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
76. Kobayashi S., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
77. Montagut C., et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18:221-223.
78. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
79. Karapetis C.S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
80. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
81. Misale S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
82. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
83. Bardelli A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.